litlas
ログインアカウント作成

Ian W. Flinn

1998–2025 年に発表

別表記
Ian W Flinn
191
論文数
47,909
被引用数
95
h 指数
182
i10 指数

被引用数

Ian W. Flinn の年別被引用数1979 年: 被引用 1 件1986 年: 被引用 1 件1992 年: 被引用 1 件1993 年: 被引用 1 件1999 年: 被引用 5 件2000 年: 被引用 16 件2001 年: 被引用 18 件2002 年: 被引用 52 件2003 年: 被引用 102 件2004 年: 被引用 100 件2005 年: 被引用 120 件2006 年: 被引用 112 件2007 年: 被引用 127 件2008 年: 被引用 156 件2009 年: 被引用 123 件2010 年: 被引用 123 件2011 年: 被引用 96 件2012 年: 被引用 108 件2013 年: 被引用 133 件2014 年: 被引用 231 件2015 年: 被引用 343 件2016 年: 被引用 235 件2017 年: 被引用 248 件2018 年: 被引用 397 件2019 年: 被引用 1,608 件2020 年: 被引用 2,111 件2021 年: 被引用 2,346 件2022 年: 被引用 2,178 件2023 年: 被引用 1,688 件2024 年: 被引用 2,787 件2025 年: 被引用 1,401 件2026 年: 被引用 25 件1980〜1985 年は被引用が無いため表示していません1987〜1991 年は被引用が無いため表示していません1994〜1998 年は被引用が無いため表示していません

引用元

国・地域

この著者を引用した国・地域の世界地図アメリカ合衆国: 引用元論文 5,398 件、この内訳の 29.4%中国: 引用元論文 1,625 件、この内訳の 8.9%ドイツ: 引用元論文 1,258 件、この内訳の 6.8%イギリス: 引用元論文 1,102 件、この内訳の 6%イタリア: 引用元論文 1,095 件、この内訳の 6%フランス: 引用元論文 905 件、この内訳の 4.9%スペイン: 引用元論文 637 件、この内訳の 3.5%オーストラリア: 引用元論文 562 件、この内訳の 3.1%カナダ: 引用元論文 559 件、この内訳の 3%スイス: 引用元論文 502 件、この内訳の 2.7%オランダ: 引用元論文 457 件、この内訳の 2.5%日本: 引用元論文 331 件、この内訳の 1.8%
0%29.4%その他 21.4%

機関

分野

  • Medicine80.8%
  • Biochemistry, Genetics and Molecular Biology10.2%
  • Immunology and Microbiology7%
  • Chemistry0.4%
  • Engineering0.4%
  • Pharmacology, Toxicology and Pharmaceutics0.3%
  • その他0.9%

トピック

  • CAR-T cell therapy research13.4%
  • Lymphoma Diagnosis and Treatment9.2%
  • Chronic Lymphocytic Leukemia Research8.4%
  • Immune Cell Function and Interaction3.5%
  • Chronic Myeloid Leukemia Treatments3%
  • Virus-based gene therapy research2.9%
  • その他59.6%

共著者

全論文

検索で開く
  1. Axicabtagene Ciloleucel CAR T-Cell Therapy in Refractory Large B-Cell Lymphoma

    著者: Sattva S. Neelapu, Frederick L. Locke, Nancy L. Bartlett, Lazaros J. Lekakis, David B. Miklos, Caron A. Jacobson, Ira Braunschweig, Olalekan O. Oluwole, Tanya Siddiqi, Yi Lin, John M. Timmerman, Patrick J. Stiff, Jonathan W. Friedberg, Ian W. Flinn, André Goy, Brian T. Hill, Mitchell R. Smith, Abhinav Deol, Umar Farooq, Peter A. McSweeney, Javier Muñoz, Irit Avivi, Januario E. Castro, Jason R. Westin, Julio C. Chávez, Armin Ghobadi, Krishna V. Komanduri, Ronald Levy, Eric D. Jacobsen, Thomas E. Witzig, Patrick M. Reagan, Adrian Bot, John M. Rossi, Lynn Navale, Yizhou Jiang, Jeff Aycock, Meg Elias, David Chang, Jeff Wiezorek, William Y. Go - New England Journal of Medicine 2017 被引用: 5,915

  2. Axicabtagene Ciloleucel as Second-Line Therapy for Large B-Cell Lymphoma

    著者: Frederick L. Locke, David B. Miklos, Caron A. Jacobson, Miguel‐Angel Perales, Marie José Kersten, Olalekan O. Oluwole, Armin Ghobadi, Aaron P. Rapoport, Joseph P. McGuirk, John M. Pagel, Javier Muñoz, Umar Farooq, Tom van Meerten, Patrick M. Reagan, Anna Sureda, Ian W. Flinn, Peter Vandenberghe, Kevin Song, Michael Dickinson, Monique C. Minnema, Peter A. Riedell, Lori A. Leslie, Sridhar Chaganti, Yin Yang, Simone Filosto, Jina Shah, Marco Schupp, Christina To, Paul Cheng, Leo I. Gordon, Jason R. Westin - New England Journal of Medicine 2021 被引用: 1,520

  3. KTE-X19 CAR T-Cell Therapy in Relapsed or Refractory Mantle-Cell Lymphoma

    著者: Michael Wang, Javier Muñoz, André Goy, Frederick L. Locke, Caron A. Jacobson, Brian T. Hill, John M. Timmerman, Houston Holmes, Samantha Jaglowski, Ian W. Flinn, Peter A. McSweeney, David B. Miklos, John M. Pagel, Marie José Kersten, Nöel Milpied, Henry C. Fung, Max S. Topp, Roch Houot, Amer Beitinjaneh, Weimin Peng, Lianqing Zheng, John M. Rossi, Rajul K. Jain, Arati V. Rao, Patrick M. Reagan - New England Journal of Medicine 2020 被引用: 1,823

  4. Long-term safety and activity of axicabtagene ciloleucel in refractory large B-cell lymphoma (ZUMA-1): a single-arm, multicentre, phase 1–2 trial

    著者: Frederick L. Locke, Armin Ghobadi, Caron A. Jacobson, David B. Miklos, Lazaros J. Lekakis, Olalekan O. Oluwole, Yi Lin, Ira Braunschweig, Brian T. Hill, John M. Timmerman, Abhinav Deol, Patrick M. Reagan, Patrick J. Stiff, Ian W. Flinn, Umar Farooq, André Goy, Peter A. McSweeney, Javier Muñoz, Tanya Siddiqi, Julio C. Chávez, Alex F. Herrera, Nancy L. Bartlett, Jeffrey S. Wiezorek, Lynn Navale, Allen Xue, Yizhou Jiang, Adrian Bot, John M. Rossi, Jaeyeon Kim, William Y. Go, Sattva S. Neelapu - The Lancet Oncology 2018 被引用: 2,251

  5. CD47 Blockade by Hu5F9-G4 and Rituximab in Non-Hodgkin’s Lymphoma

    著者: Ranjana H. Advani, Ian W. Flinn, Leslie Popplewell, Andres Forero, Nancy L. Bartlett, Nilanjan Ghosh, Justin Kline, Mark Roschewski, Ann S. LaCasce, Graham P. Collins, Thu Ha Tran, Judith Lynn, James Y. Chen, Jens-Peter Volkmer, Balaji Agoram, Jie Huang, Ravindra Majeti, Irving L. Weissman, Chris H. Takimoto, Mark P. Chao, Sonali M. Smith - New England Journal of Medicine 2018 被引用: 1,120

  6. Second-Line Tisagenlecleucel or Standard Care in Aggressive B-Cell Lymphoma

    著者: Michael R. Bishop, Michael Dickinson, Duncan Purtill, Pere Barba, Armando Santoro, Nada Hamad, Koji Kato, Anna Sureda, Richard Greil, Catherine Thieblemont, Franck Morschhauser, Martin Janz, Ian W. Flinn, Werner Rabitsch, Yok‐Lam Kwong, Marie José Kersten, Monique C. Minnema, Harald Holte, Esther Hian Li Chan, Joaquín Martínez‐López, Antonia Müller, Richard T. Maziarz, Joseph P. McGuirk, Emmanuel Bachy, Steven Le Gouill, Martin Dreyling, Hideo Harigae, David A. Bond, Charalambos Andreadis, Peter A. McSweeney, Mohamed A. Kharfan‐Dabaja, Simon Newsome, Evgeny Degtyarev, Rakesh Awasthi, Christopher del Corral, Giovanna Andreola, Aisha Masood, Stephen J. Schuster, Ulrich Jäger, Peter Borchmann, Jason R. Westin - New England Journal of Medicine 2021 被引用: 520

  7. Enasidenib in mutant IDH2 relapsed or refractory acute myeloid leukemia

    著者: Eytan M. Stein, Courtney D. DiNardo, Daniel A. Pollyea, Amir T. Fathi, Gail J. Roboz, Jessica K. Altman, Richard M. Stone, Daniel J. DeAngelo, Ross L. Levine, Ian W. Flinn, Hagop M. Kantarjian, Robert H. Collins, Manish R. Patel, Arthur E. Frankel, Anthony S. Stein, Mikkael A. Sekeres, Ronan Swords, Bruno C. Medeiros, Christophe Willekens, Paresh Vyas, Alessandra Tosolini, Qiang Xu, Robert Knight, Katharine Yen, Sam Agresta, Stéphane de Botton, Martin S. Tallman - Blood 2017 被引用: 1,469

  8. 5-Year Follow-Up Supports Curative Potential of Axicabtagene Ciloleucel in Refractory Large B-Cell Lymphoma (ZUMA-1)

    著者: Sattva S. Neelapu, Caron A. Jacobson, Armin Ghobadi, David B. Miklos, Lazaros J. Lekakis, Olalekan O. Oluwole, Yi Lin, Ira Braunschweig, Brian T. Hill, John M. Timmerman, Abhinav Deol, Patrick M. Reagan, Patrick J. Stiff, Ian W. Flinn, Umar Farooq, André Goy, Peter A. McSweeney, Javier Muñoz, Tanya Siddiqi, Julio C. Chávez, Alex F. Herrera, Nancy L. Bartlett, Adrian A. Bot, Rhine R. Shen, Jinghui Dong, Kanwarjit Singh, Harry Miao, Jaeyeon Kim, Yan Zheng, Frederick L. Locke - Blood 2023 被引用: 228

  9. Three-Year Follow-Up of KTE-X19 in Patients With Relapsed/Refractory Mantle Cell Lymphoma, Including High-Risk Subgroups, in the ZUMA-2 Study

    著者: Michael Wang, Javier Muñoz, André Goy, Frederick L. Locke, Caron A. Jacobson, Brian T. Hill, John M. Timmerman, Houston Holmes, Samantha Jaglowski, Ian W. Flinn, Peter A. McSweeney, David B. Miklos, John M. Pagel, Marie José Kersten, Krimo Bouabdallah, Rashmi Khanal, Max S. Topp, Roch Houot, Amer Beitinjaneh, Weimin Peng, Xiang Fang, Rhine R. Shen, Rubina Siddiqi, Ioana Kloos, Patrick M. Reagan - Journal of Clinical Oncology 2022 被引用: 318

  10. Single-Agent Mosunetuzumab Shows Durable Complete Responses in Patients With Relapsed or Refractory B-Cell Lymphomas: Phase I Dose-Escalation Study

    著者: Lihua E. Budde, Sarit Assouline, Laurie H. Sehn, Stephen J. Schuster, Sung-Soo Yoon, Dok Hyun Yoon, Matthew J. Matasar, Francesc Bosch, Won Seog Kim, Loretta J. Nastoupil, Ian W. Flinn, Mazyar Shadman, Catherine Diefenbach, Carol O'Hear, Huang Huang, Antonia Kwan, Chi-Chung Li, Emily C. Piccione, Michael C. Wei, Shen Yin, Nancy L. Bartlett - Journal of Clinical Oncology 2021 被引用: 290

  11. Acalabrutinib with or without obinutuzumab versus chlorambucil and obinutuzumab for treatment-naive chronic lymphocytic leukaemia (ELEVATE-TN): a randomised, controlled, phase 3 trial

    著者: Jeff P. Sharman, Miklós Egyed, Wojciech Jurczak, Alan P Skarbnik, John M. Pagel, Ian W. Flinn, Manali Kamdar, Talha Munir, Renata Walewska, Gillian Corbett, Laura Fogliatto, Yair Herishanu, Versha Banerji, Steven Coutré, George Follows, Patricia Walker, Karin Karlsson, Paolo Ghia, Ann Janssens, Florence Cymbalista, Jennifer A. Woyach, Gilles Salles, William G. Wierda, Raquel Izumi, Veerendra Munugalavadla, Priti Patel, Min Hui Wang, Sofia Wong, John C. Byrd - The Lancet 2020 被引用: 612

  12. Zanubrutinib versus bendamustine and rituximab in untreated chronic lymphocytic leukaemia and small lymphocytic lymphoma (SEQUOIA): a randomised, controlled, phase 3 trial

    著者: Constantine S. Tam, Jennifer R. Brown, Brad S. Kahl, Paolo Ghia, Krzysztof Giannopoulos, Wojciech Jurczak, Martin Šimkovič, Mazyar Shadman, Anders Österborg, Luca Laurenti, Patricia Walker, Stephen Opat, Henry Chan, Hanna Ciepłuch, Richard Greil, Monica Tani, Marek Trněný, Danielle M. Brander, Ian W. Flinn, Sebastian Grosicki, Emma Verner, Alessandra Tedeschi, Jianyong Li, Tian Tian, Lei Zhou, Carol Marimpietri, Jason C. Paik, Aileen Cohen, Jane Huang, Tadeusz Robak, Peter Hillmen - The Lancet Oncology 2022 被引用: 278

  13. Pirtobrutinib after a Covalent BTK Inhibitor in Chronic Lymphocytic Leukemia

    著者: Anthony R. Mato, Jennifer A. Woyach, Jennifer R. Brown, Paolo Ghia, Krish Patel, Toby A. Eyre, Talha Munir, Ewa Lech‐Marańda, Nicole Lamanna, Constantine S. Tam, Nirav N. Shah, Catherine C. Coombs, Chaitra S. Ujjani, Bita Fakhri, Chan Y. Cheah, Manish R. Patel, Alvaro J. Alencar, Jonathon B. Cohen, James N. Gerson, Ian W. Flinn, Shuo Ma, Deepa Jagadeesh, Joanna Rhodes, Francisco J. Hernandez‐Ilizaliturri, Pier Luigi Zinzani, John F. Seymour, Minna Balbas, Binoj C. Nair, Paolo Abada, Chunxiao Wang, Amy S. Ruppert, Denise Wang, Donald E. Tsai, William G. Wierda, Wojciech Jurczak - New England Journal of Medicine 2023 被引用: 217

  14. Pirtobrutinib in relapsed or refractory B-cell malignancies (BRUIN): a phase 1/2 study

    著者: Anthony R. Mato, Nirav N. Shah, Wojciech Jurczak, Chan Y. Cheah, John M. Pagel, Jennifer A. Woyach, Bita Fakhri, Toby A. Eyre, Nicole Lamanna, Manish R. Patel, Alvaro J. Alencar, Ewa Lech‐Marańda, William G. Wierda, Catherine C. Coombs, James N. Gerson, Paolo Ghia, Steven Le Gouill, David Lewis, Suchitra Sundaram, Jonathon B. Cohen, Ian W. Flinn, Constantine S. Tam, Minal Barve, Bryone J. Kuss, Justin Taylor, Omar Abdel‐Wahab, Stephen J. Schuster, M. Lia Palomba, Katharine L. Lewis, Lindsey E. Roeker, Matthew S. Davids, Xuan Tan, Timothy S. Fenske, Johan Wallin, Donald E. Tsai, Nora Ku, Edward Y. Zhu, Jessica Chen, Ming Yin, Binoj C. Nair, Kevin Ebata, Narasimha Marella, Jennifer R. Brown, Michael Wang - The Lancet 2021 被引用: 454

  15. Targeting BTK with Ibrutinib in Relapsed Chronic Lymphocytic Leukemia

    著者: John C. Byrd, Richard R. Furman, Steven Coutré, Ian W. Flinn, Jan A. Burger, Kristie A. Blum, Barbara Grant, Jeff P. Sharman, Morton Coleman, William G. Wierda, Jeffrey A. Jones, Weiqiang Zhao, Nyla A. Heerema, Amy J. Johnson, Juthamas Sukbuntherng, Betty Chang, Fong Clow, Eric Hedrick, Joseph J. Buggy, Danelle F. James, Susan O’Brien - New England Journal of Medicine 2013 被引用: 2,249

  16. Magrolimab in Combination With Azacitidine in Patients With Higher-Risk Myelodysplastic Syndromes: Final Results of a Phase Ib Study

    著者: David A. Sallman, Monzr M. Al Malki, Adam S. Asch, Eunice S. Wang, Joseph G. Jurcic, Terrence Bradley, Ian W. Flinn, Daniel A. Pollyea, Suman Kambhampati, Tiffany Tanaka, Joshua F. Zeidner, Guillermo Garcia‐Manero, Deepa Jeyakumar, Rami S. Komrokji, Jeffrey E. Lancet, Hagop M. Kantarjian, Lin Gu, Yajia Zhang, Anderson Tan, Mark P. Chao, Carol O’Hear, Giridharan Ramsingh, Indu Lal, Paresh Vyas, Naval Daver - Journal of Clinical Oncology 2023 被引用: 171

  17. A Novel Autologous CAR-T Therapy, YTB323, with Preserved T-cell Stemness Shows Enhanced CAR T-cell Efficacy in Preclinical and Early Clinical Development

    著者: Michael Dickinson, Pere Barba, Ulrich Jäger, Nirav N. Shah, Didier Blaise, Javier Briones, Leyla Shune, Nicolas Boissel, Attilio Bondanza, Luisa Mariconti, Anne-Laure Marchal, David S. Quinn, Jennifer Yang, Andrew Price, Akash Sohoni, Louise M. Treanor, Elena J. Orlando, Jennifer Mataraza, Jaclyn Davis, Darlene Lu, Xu Zhu, Boris Engels, Laure Moutouh–de Parseval, Jennifer L. Brogdon, Michele Moschetta, Ian W. Flinn - Cancer Discovery 2023 被引用: 121

  18. Phase I Study of the CD47 Blocker TTI-621 in Patients with Relapsed or Refractory Hematologic Malignancies

    著者: Stephen M. Ansell, Michael B. Maris, Alexander M. Lesokhin, Robert W. Chen, Ian W. Flinn, Ahmed Sawas, Mark D. Minden, Diego Villa, Mary‐Elizabeth M. Percival, Anjali S. Advani, James M. Foran, Steven M. Horwitz, Matthew Mei, Jasmine Zain, Kerry J. Savage, Christiane Querfeld, Oleg E. Akilov, Lisa D. Johnson, Tina Catalano, Penka S. Petrova, Robert A. Uger, Eric L. Sievers, Anca Milea, Kathleen Roberge, Yaping Shou, Owen A. O’Connor - Clinical Cancer Research 2021 被引用: 196

  19. Consensus recommendations on the management of toxicity associated with CD3×CD20 bispecific antibody therapy

    著者: Jennifer L. Crombie, Tara Graff, Lorenzo Falchi, Yasmin Karimi, Rajat Bannerji, Loretta J. Nastoupil, Catherine Thiéblemont, Rénata Ursu, Nancy L. Bartlett, Victoria Nachar, J. Weiss, Jane Osterson, Krish Patel, Joshua Brody, Jeremy S. Abramson, Matthew A. Lunning, Nirav N. Shah, Ayed O. Ayed, Manali Kamdar, Benjamin M. Parsons, Paolo F. Caimi, Ian W. Flinn, Alex F. Herrera, Jeffrey P. Sharman, Marshall McKenna, Philippe Armand, Brad S. Kahl, Sonali M. Smith, Andrew D. Zelenetz, Lihua E. Budde, Martin Hutchings, Tycel Phillips, Michael Dickinson - Blood 2024 被引用: 131

  20. Long-term outcomes with frontline nilotinib versus imatinib in newly diagnosed chronic myeloid leukemia in chronic phase: ENESTnd 10-year analysis

    著者: Hagop M. Kantarjian, Timothy P. Hughes, Richard A. Larson, Dong‐Wook Kim, Surapol Issaragrisil, Philipp le Coutre, Gabriel Étienne, Carla Boquimpani, Ricardo Pasqüini, Richard E. Clark, Viviane Dubruille, Ian W. Flinn, Sławomira Kyrcz‐Krzemień, Ewa Mędraś, Maria Aparecida Zanichelli, Israel Bendit, Silvia Cacciatore, Ksenia Titorenko, Paola Aimone, Giuseppe Saglio, Andreas Hochhaus - Leukemia 2021 被引用: 351

  21. CD19 target evasion as a mechanism of relapse in large B-cell lymphoma treated with axicabtagene ciloleucel

    著者: Vicki Plaks, John M. Rossi, Justin Chou, Linghua Wang, Soumya Poddar, Guangchun Han, Zixing Wang, Shao-Qing Kuang, Fuliang Chu, R. Eric Davis, Francisco Vega, Zahid Bashir, Caron A. Jacobson, Frederick L. Locke, Patrick M. Reagan, Scott J. Rodig, Lazaros J. Lekakis, Ian W. Flinn, David B. Miklos, Adrian Bot, Sattva S. Neelapu - Blood 2021 被引用: 189

  22. AUGMENT: A Phase III Study of Lenalidomide Plus Rituximab Versus Placebo Plus Rituximab in Relapsed or Refractory Indolent Lymphoma

    著者: John P. Leonard, Marek Trněný, Koji Izutsu, Nathan Fowler, Xiaonan Hong, Jun Zhu, Huilai Zhang, Fritz Offner, Adriana Scheliga, Grzegorz S. Nowakowski, Antonio Pinto, Francesca Re, Laura Maria Fogliatto, Phillip Scheinberg, Ian W. Flinn, Cláudia Moreira, José Cabeçadas, David Liu, Stacey Kalambakas, Pierre Fustier, Chengqing Wu, John G. Gribben, for the AUGMENT Trial Investigators - Journal of Clinical Oncology 2019 被引用: 421

  23. Efficacy and safety in a 4-year follow-up of the ELEVATE-TN study comparing acalabrutinib with or without obinutuzumab versus obinutuzumab plus chlorambucil in treatment-naïve chronic lymphocytic leukemia

    著者: Jeff P. Sharman, Miklós Egyed, Wojciech Jurczak, Alan P Skarbnik, John M. Pagel, Ian W. Flinn, Manali Kamdar, Talha Munir, Renata Walewska, Gillian Corbett, Laura Fogliatto, Yair Herishanu, Versha Banerji, Steven Coutré, George Follows, Patricia Walker, Karin Karlsson, Paolo Ghia, Ann Janssens, Florence Cymbalista, Jennifer A. Woyach, Emmanuelle Ferrant, William G. Wierda, Veerendra Munugalavadla, Ting Yu, Min Hui Wang, John C. Byrd - Leukemia 2022 被引用: 200

  24. Ibrutinib Plus Venetoclax for First-Line Treatment of Chronic Lymphocytic Leukemia: Primary Analysis Results From the Minimal Residual Disease Cohort of the Randomized Phase II CAPTIVATE Study

    著者: William G. Wierda, John N. Allan, Tanya Siddiqi, Thomas J. Kipps, Stephen Opat, Alessandra Tedeschi, Xavier C. Badoux, Bryone J. Kuss, Sharon Jackson, Carol Moreno, Ryan Jacobs, John M. Pagel, Ian W. Flinn, Yvonne Pak, Cathy Zhou, Edith Szafer‐Glusman, Joi Ninomoto, James P. Dean, Danelle F. James, Paolo Ghia, Constantine S. Tam - Journal of Clinical Oncology 2021 被引用: 229